Related Experiment Video

Updated: Jun 6, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer

Kathryn A Clausen1, Kimberly R Blish, Charles E Birse

  • 1Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. kclausen@wfubmc.edu

Breast Cancer Research and Treatment
|November 30, 2010
PubMed

Insights

Sclerostin domain containing 1 (SOSTDC1) is reduced in breast cancer, with lower SOSTDC1 linked to poorer survival. This protein selectively impacts BMP and Wnt signaling pathways, suggesting its potential as a therapeutic target.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Background:

  • Sclerostin domain containing 1 (SOSTDC1) protein influences development and cancer by modulating bone morphogenetic protein (BMP) and wingless/int (Wnt) signaling.
  • Dysregulation of BMP and Wnt signaling is implicated in breast cancer progression.

Purpose of the Study:

  • To investigate the role and disruption of SOSTDC1 signaling in breast cancer.
  • To determine the correlation between SOSTDC1 expression levels and breast cancer patient outcomes.

Main Methods:

  • Dot blot analysis of SOSTDC1 mRNA expression in breast tissue.
  • Correlation of Affymetrix microarray data with patient survival using Kaplan-Meier plots.
  • Immunohistochemistry to assess SOSTDC1 protein levels and clinical parameters.

Main Results:

  • SOSTDC1 expression is reduced in breast cancer compared to normal tissue.
  • Higher SOSTDC1 mRNA levels correlate with improved patient survival and increased distant metastasis-free survival.
  • SOSTDC1 protein levels decrease with increasing tumor size and disease stage.
  • SOSTDC1 selectively inhibits BMP-7-induced Smad phosphorylation, without affecting BMP-2 or Wnt3a signaling.

Conclusions:

  • SOSTDC1 is downregulated in breast cancer, and its reduced expression is associated with adverse clinical outcomes.
  • SOSTDC1 acts as a differential regulator of BMP and Wnt signaling pathways in breast cancer cells.
  • SOSTDC1 represents a clinically significant extracellular regulator in breast cancer, potentially offering therapeutic avenues.

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...